MCID: PNC041
MIFTS: 51

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 12 15 17 71
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 49 C9120
UMLS 71 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and cholangiocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs leucovorin and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, t cells and lymph node.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 239, show less)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 33.4 UCA1 PVT1 MIR21 MIR155 MALAT1 LINC00673
2 cholangiocarcinoma 31.5 UCA1 MIR21 MALAT1 H19 DAPK1 AFAP1-AS1
3 retinitis pigmentosa 11 31.2 UCA1 PVT1 HOTAIR
4 lung cancer susceptibility 3 31.1 MIR31HG MIR21 MALAT1 HOTAIR H19 DAPK1
5 b-cell lymphoma 31.0 PVT1 MIR21 MIR155 MALAT1 HOTAIR DAPK1
6 kidney cancer 30.9 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
7 gastrointestinal system cancer 30.8 MIR21 MIR155 MALAT1 HOTAIR H19
8 small cell cancer of the lung 30.8 MIR21 MALAT1 HOTTIP HOTAIR
9 gallbladder cancer 30.7 UCA1 MALAT1 HOTAIR H19 AFAP1-AS1
10 osteogenic sarcoma 30.7 UCA1 TUSC7 PVT1 MALAT1 HOTTIP HOTAIR
11 clear cell renal cell carcinoma 30.7 PVT1 MIR21 MIR155 MALAT1
12 hepatocellular carcinoma 30.7 UCA1 TUSC7 PVT1 MIR21 MIR155 MALAT1
13 renal cell carcinoma, nonpapillary 30.6 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
14 pituitary adenoma 30.6 MALAT1 HOTAIR H19
15 esophageal cancer 30.6 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
16 nasopharyngeal carcinoma 30.6 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
17 leukemia, acute myeloid 30.5 UCA1 TUSC7 MIR21 MIR155 MALAT1 HOTAIRM1
18 gastric cancer 30.0 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
19 colorectal cancer 29.6 UCA1 TUSC7 TMEM238L PVT1 MIR21 MIR155
20 adenocarcinoma 11.6
21 pancreatic cancer 5 11.5
22 pancreatic adenocarcinoma 11.0
23 pancreatitis 10.7
24 pancreas disease 10.7
25 pancreatic ductal carcinoma 10.7
26 pancreatic agenesis 1 10.7
27 autoimmune pancreatitis 10.6
28 microvascular complications of diabetes 3 10.6 PVT1 MIR21 MALAT1
29 polymyositis 10.6 MIR21 MIR155
30 severe combined immunodeficiency 10.6
31 triple-receptor negative breast cancer 10.6 MALAT1 HOTAIR
32 laryngeal squamous cell carcinoma 10.6 MIR21 MALAT1 HOTAIR H19
33 intrahepatic cholangiocarcinoma 10.6
34 prostate disease 10.6 MIR21 MIR155 MALAT1 H19
35 thyroid cancer, nonmedullary, 1 10.6 MALAT1 HOTTIP HOTAIR H19
36 neutropenia 10.5
37 oral squamous cell carcinoma 10.5 UCA1 MIR21 MIR155 MALAT1 HOTAIR H19
38 tongue disease 10.5 UCA1 MIR21 LINC00673
39 hypoxia 10.5
40 lymphoma, hodgkin, classic 10.5 PVT1 MIR21 MIR155
41 myeloma, multiple 10.5 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
42 bladder urothelial carcinoma 10.5 UCA1 PVT1 MALAT1 HOTAIR
43 pancreatitis, hereditary 10.5
44 neuroendocrine tumor 10.5
45 esophagus squamous cell carcinoma 10.4 HOTAIR AFAP1-AS1
46 glioma 10.4 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
47 tongue squamous cell carcinoma 10.4 UCA1 MIR21 MALAT1 LINC00673 HOTTIP AFAP1-AS1
48 miyoshi muscular dystrophy 1 10.4 MIR21 MIR155
49 obstructive jaundice 10.4
50 acute pancreatitis 10.4
51 coronary heart disease 1 10.4 MIR155 HOTTIP H19
52 glioma susceptibility 1 10.4 TUSC7 MIR21 MALAT1 HOTAIRM1 HOTAIR H19
53 squamous cell carcinoma 10.4 UCA1 TUSC7 MALAT1 HOTAIR H19 DAPK1
54 cystadenoma 10.4
55 astrocytoma 10.4 UCA1 TUSC7 PVT1 MIR21 HOTAIRM1 HOTAIR
56 thyroid gland cancer 10.4 UCA1 PVT1 MIR21 MALAT1 HOTAIR H19
57 cervical cancer 10.4 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
58 lynch syndrome 10.3
59 cytokine deficiency 10.3
60 bladder cancer 10.3 UCA1 PVT1 MIR31HG MIR21 MALAT1 HOTAIR
61 malignant glioma 10.3 TUSC7 PVT1 MALAT1 HOTTIP HOTAIRM1 HOTAIR
62 prostate cancer 10.3
63 wilms tumor 5 10.3
64 duodenum adenocarcinoma 10.3
65 pancreatic endocrine carcinoma 10.3
66 neuroendocrine carcinoma 10.3
67 adenosquamous carcinoma 10.3
68 tubular adenocarcinoma 10.3
69 ovarian serous cystadenocarcinoma 10.3
70 in situ carcinoma 10.3
71 melanoma 10.2 UCA1 PVT1 MALAT1 LINC00673 HOTAIRM1 HOTAIR
72 retinoblastoma 10.2
73 familial adenomatous polyposis 10.2
74 hyperinsulinism 10.2
75 acinar cell carcinoma 10.2
76 hyperglycemia 10.2
77 familial retinoblastoma 10.2
78 diabetes mellitus 10.2
79 47,xyy 10.2
80 acute sensory ataxic neuropathy 10.2
81 leukemia, chronic myeloid 10.2 UCA1 MIR155 HOTAIR H19
82 autoimmune disease 10.1
83 fibrosis of extraocular muscles, congenital, 1 10.1
84 pancreas, annular 10.1
85 peutz-jeghers syndrome 10.1
86 wilms tumor 1 10.1
87 ataxia-telangiectasia 10.1
88 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
89 body mass index quantitative trait locus 11 10.1
90 body mass index quantitative trait locus 9 10.1
91 body mass index quantitative trait locus 8 10.1
92 gastrointestinal stromal tumor 10.1
93 body mass index quantitative trait locus 4 10.1
94 body mass index quantitative trait locus 10 10.1
95 body mass index quantitative trait locus 7 10.1
96 body mass index quantitative trait locus 12 10.1
97 body mass index quantitative trait locus 14 10.1
98 pancreatic cancer 4 10.1
99 body mass index quantitative trait locus 18 10.1
100 body mass index quantitative trait locus 19 10.1
101 body mass index quantitative trait locus 20 10.1
102 exanthem 10.1
103 thrombosis 10.1
104 portal vein thrombosis 10.1
105 choledocholithiasis 10.1
106 telangiectasis 10.1
107 islet cell tumor 10.1
108 hepatitis b 10.1
109 bilirubin metabolic disorder 10.1
110 tic disorder 10.1
111 glioblastoma multiforme 10.1
112 gastric adenocarcinoma 10.1
113 pancreatic serous cystadenoma 10.1
114 avian influenza 10.1
115 bile duct cancer 10.1
116 lymphopenia 10.1
117 thyroid hyalinizing trabecular adenoma 10.1
118 adenoma 10.1
119 cholangitis 10.1
120 pulmonary embolism 10.1
121 stomatitis 10.1
122 back pain 10.1
123 autoimmune pancreatitis type 1 10.1
124 neuroendocrine neoplasm of pancreas 10.1
125 rare tumor 10.1
126 polyploidy 10.1
127 mesothelioma, malignant 10.0
128 ovarian cancer 10.0
129 pancreatic cancer 3 10.0
130 zollinger-ellison syndrome 10.0
131 anthracosilicosis 10.0
132 giant cell tumor 10.0
133 signet ring cell adenocarcinoma 10.0
134 mucinous cystadenocarcinoma 10.0
135 lymph node disease 10.0
136 aortic aneurysm, familial abdominal, 1 10.0
137 alcohol dependence 10.0
138 breast cancer 10.0
139 diabetes mellitus, noninsulin-dependent 10.0
140 multiple endocrine neoplasia, type i 10.0
141 gastric cancer, hereditary diffuse 10.0
142 myhre syndrome 10.0
143 thoracolaryngopelvic dysplasia 10.0
144 thrombophilia due to thrombin defect 10.0
145 tuberous sclerosis 1 10.0
146 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
147 cystic fibrosis 10.0
148 leprosy 3 10.0
149 proteasome-associated autoinflammatory syndrome 1 10.0
150 sjogren syndrome 10.0
151 thrombocytopenia 3 10.0
152 thymoma, familial 10.0
153 squamous cell carcinoma, head and neck 10.0
154 wiskott-aldrich syndrome 10.0
155 ataxia and polyneuropathy, adult-onset 10.0
156 panbronchiolitis, diffuse 10.0
157 body mass index quantitative trait locus 1 10.0
158 endometrial cancer 10.0
159 human immunodeficiency virus type 1 10.0
160 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
161 seborrhea-like dermatitis with psoriasiform elements 10.0
162 fatty liver disease, nonalcoholic 1 10.0
163 prostate cancer, hereditary, 2 10.0
164 pachyonychia congenita 3 10.0
165 diarrhea 9 10.0
166 inflammatory bowel disease 10.0
167 polycystic liver disease 10.0
168 sleep apnea 10.0
169 limb ischemia 10.0
170 gastrointestinal carcinoma 10.0
171 lymphoma 10.0
172 mucositis 10.0
173 polycystic kidney disease 10.0
174 cholelithiasis 10.0
175 lymphocytic leukemia 10.0
176 glucose intolerance 10.0
177 portal hypertension 10.0
178 sarcoma 10.0
179 diphtheria 10.0
180 allergic hypersensitivity disease 10.0
181 diarrhea 10.0
182 tuberous sclerosis 10.0
183 polyneuropathy 10.0
184 thrombocytopenia 10.0
185 rectum cancer 10.0
186 neuroma 10.0
187 constipation 10.0
188 thrombophilia 10.0
189 benign mesothelioma 10.0
190 breast ductal carcinoma 10.0
191 acute kidney failure 10.0
192 interstitial lung disease 10.0
193 cystadenocarcinoma 10.0
194 thymoma 10.0
195 fibrosarcoma 10.0
196 duodenal obstruction 10.0
197 aortic aneurysm 10.0
198 plasmacytoma 10.0
199 insulinoma 10.0
200 pancreatic cystadenoma 10.0
201 spindle cell sarcoma 10.0
202 carcinosarcoma 10.0
203 hypokalemia 10.0
204 liver cirrhosis 10.0
205 pancreatic adenosquamous carcinoma 10.0
206 hereditary breast ovarian cancer syndrome 10.0
207 peripheral nervous system disease 10.0
208 pancreatic acinar cell adenocarcinoma 10.0
209 distal biliary tract carcinoma 10.0
210 combined t cell and b cell immunodeficiency 10.0
211 pancreatoblastoma 10.0
212 peptic ulcer disease 10.0
213 pancreatic intraductal papillary-mucinous neoplasm 10.0
214 gastrointestinal system disease 10.0
215 end stage renal failure 10.0
216 influenza 10.0
217 lung disease 10.0
218 neuropathy 10.0
219 autosomal dominant polycystic kidney disease 10.0
220 hypoglycemia 10.0
221 diffuse gastric cancer 10.0
222 glucagonoma 10.0
223 hansen's disease 10.0
224 pancreatic adenoma 10.0
225 splenomegaly 10.0
226 triploidy 10.0
227 multiple endocrine neoplasia 10.0
228 aneurysm 10.0
229 pituitary tumors 10.0
230 posttransplant acute limbic encephalitis 10.0
231 rapidly involuting congenital hemangioma 10.0
232 acinar cell carcinoma of pancreas 10.0
233 recurrent acute pancreatitis 10.0
234 argyria 10.0
235 pik3ca-related overgrowth syndrome 10.0
236 discoid lupus erythematosus 10.0
237 adenoma of pancreas 10.0
238 parkinson disease, late-onset 10.0 MIR21 MALAT1 HOTAIR H19 DAPK1
239 lung cancer 9.8 UCA1 TUSC7 PVT1 MIR31HG MIR21 MIR155

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, pruritus, icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 141, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 3 58-05-9 6006 143
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
3
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
5
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
6 Vitamin B9 Phase 3
7 Folate Phase 3
8 Hematinics Phase 3
9 Vitamin B Complex Phase 3
10 Antidotes Phase 3
11
asparaginase Phase 3
12 Calcium, Dietary Phase 3
13 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
14 Viscosupplements Phase 3
15 Adjuvants, Immunologic Phase 3
16
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
19
Enoxaparin Approved Phase 2 9005-49-6 772
20
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
21
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
22
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
23
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
24
Olaparib Approved Phase 2 763113-22-0 23725625
25
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
26
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
27
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
28
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
29
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
30
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
31
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
32
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
33
Coal tar Approved Phase 1, Phase 2 8007-45-2
34
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
35
nivolumab Approved Phase 1, Phase 2 946414-94-4
36
Metformin Approved Phase 2 657-24-9 14219 4091
37
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
38
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
39
Durvalumab Approved, Investigational Phase 2 1428935-60-7
40
Pembrolizumab Approved Phase 2 1374853-91-4
41
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
42
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
43
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
44
Cediranib Investigational Phase 2 288383-20-0 9933475
45
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
46 Misonidazole Investigational Phase 2 13551-87-6
47
Tremelimumab Investigational Phase 2 745013-59-6
48 Anti-Bacterial Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50
Liposomal doxorubicin Phase 2 31703
51 HIV Protease Inhibitors Phase 2
52
protease inhibitors Phase 2
53 Antiemetics Phase 2
54 Hormone Antagonists Phase 2
55 BB 1101 Phase 2
56 Antineoplastic Agents, Hormonal Phase 2
57 glucocorticoids Phase 2
58 acivicin Phase 2
59 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
60 Hormones Phase 2
61 Angiogenesis Inhibitors Phase 1, Phase 2
62 Interleukin-2 Phase 2
63 Analgesics, Non-Narcotic Phase 2
64 Mitogens Phase 2
65 Analgesics Phase 2
66 Vidarabine Phosphate Phase 2
67 Ergocalciferols Phase 2
68 Vitamin D2 Phase 2
69 Calciferol Phase 2
70 Anti-Inflammatory Agents Phase 2
71 Cyclooxygenase Inhibitors Phase 2
72 Anti-Inflammatory Agents, Non-Steroidal Phase 2
73 Cyclooxygenase 2 Inhibitors Phase 2
74 Anesthetics Phase 2
75 Immunoglobulin G Phase 1, Phase 2
76 Paraproteins Phase 1, Phase 2
77 Myeloma Proteins Phase 1, Phase 2
78 Antirheumatic Agents Phase 1, Phase 2
79 Alkylating Agents Phase 1, Phase 2
80 Folic Acid Antagonists Phase 1, Phase 2
81 Immunotoxins Phase 1, Phase 2
82 Vaccines Phase 1, Phase 2
83
s 1 (combination) Phase 2
84 Hypoglycemic Agents Phase 2
85 Antibodies, Monoclonal Phase 2
86 Antineoplastic Agents, Immunological Phase 2
87 Immunoglobulins Phase 2
88 Antibodies Phase 2
89
Etoposide Approved Phase 1 33419-42-0 36462
90
Palbociclib Approved, Investigational Phase 1 571190-30-2 11431660 5005498 5330286
91
Tocopherol Approved, Investigational Phase 1 1406-66-2, 54-28-4 14986
92
Losartan Approved Phase 1 114798-26-4 3961
93
Angiotensin II Approved, Investigational Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198
94
Talimogene laherparepvec Approved, Experimental, Investigational Phase 1 1187560-31-1
95
Tofacitinib Approved, Investigational Phase 1 477600-75-2
96
Atezolizumab Approved, Investigational Phase 1 1380723-44-3
97
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
98
afatinib Approved Phase 1 850140-72-6, 439081-18-2 10184653
99
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
100
Ipilimumab Approved Phase 1 477202-00-9
101
Idelalisib Approved Phase 1 870281-82-6
102
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
103
Threonine Approved, Nutraceutical Phase 1 72-19-5 6288
104
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
105
Tyrosine Approved, Investigational, Nutraceutical Phase 1 60-18-4 6057
106 Tocotrienol Investigational Phase 1 6829-55-6
107 Interleukin 1 Receptor Antagonist Protein Phase 1
108 neurokinin A Phase 1
109
Substance P Phase 1 33507-63-0 44359816
110 Etoposide phosphate Phase 1
111 Tocopherols Phase 1
112 Tocotrienols Phase 1
113 Liver Extracts Phase 1
114 Anti-Arrhythmia Agents Phase 1
115 Antihypertensive Agents Phase 1
116 Angiotensin II Type 1 Receptor Blockers Phase 1
117 Angiotensin Receptor Antagonists Phase 1
118 Giapreza Phase 1
119 Angiotensinogen Phase 1
120 Cola Phase 1
121 interferons Phase 1
122 Interferon Inducers Phase 1
123 Poly ICLC Phase 1
124
Serine Investigational, Nutraceutical Phase 1 56-45-1 5951
125
Bethanechol Approved Early Phase 1 674-38-4 2370
126
tannic acid Approved 1401-55-4
127
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
128
carbamide peroxide Approved Early Phase 1 124-43-6
129
Sulforaphane Investigational 142825-10-3, 4478-93-7 5350
130
Butyric Acid Experimental, Investigational Early Phase 1 107-92-6 264
131 Sulforafan
132 Calamus
133 Fluoroazomycin arabinoside
134 Radiopharmaceuticals
135 Neurotransmitter Agents Early Phase 1
136 Autonomic Agents Early Phase 1
137 Narcotics
138 Muscarinic Agonists Early Phase 1
139 Cholinergic Agents Early Phase 1
140 Trichostatin A
141
Ethylene Early Phase 1 74-85-1 6325

Interventional clinical trials:

(showing 215, show less)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03943667 Phase 3 Gemcitabine;Paclitaxel
4 Norwegian Pancreatic Cancer Trial (NorPACT) - 1: Norwegian Multicentre Un-blinded Phase III Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected Recruiting NCT02919787 Phase 2, Phase 3 5-FU;Oxaliplatine;Irinotecan;5-FU;Oxaliplatine;Irinotecan
5 Randomized Controlled Trial for the Evaluation of Complete Microscopic Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (RAMPS) Recruiting NCT03679169 Phase 3
6 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
7 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial) Not yet recruiting NCT03317886 Phase 3
8 A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma Not yet recruiting NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
9 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
10 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
11 Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer Unknown status NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
12 Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
13 Intraoperative Detection of Cancer Tissue in Pancreatic Adenocarcinoma Using a VEGF-targeted Optical Fluorescent Imaging Tracer, A Multicentre Feasibility Dose Escalation Study Unknown status NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
14 PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER Unknown status NCT02511223 Phase 2 OLAPARIB
15 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
16 A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
17 An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
18 A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
19 A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Completed NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
20 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
21 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
22 Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
23 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
24 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
25 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
26 A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer Completed NCT01693419 Phase 2 GES (Gemcitabine, Erlotinib, S-1)
27 A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed NCT01660711 Phase 2 5 Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
28 A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03915444 Phase 2 nab-Paclitaxel + Cisplatin + Gemcitabine
29 A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
30 Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer Recruiting NCT03636308 Phase 2 nanoparticle albumin-bound paclitaxel;S1;Gemcitabine
31 Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
32 A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
33 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
34 A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
35 A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
36 PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy Recruiting NCT03404960 Phase 1, Phase 2 Niraparib + Nivolumab;Niraparib + Ipilimumab
37 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;Emactuzumab;RO6874281
38 A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX Recruiting NCT04010552 Phase 2 NALRINOX combination
39 A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients With Pancreatic Ductal Adenocarcinoma Recruiting NCT04005690 Phase 2 Cobimetinib;Olaparib
40 An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
41 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
42 A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT04054362 Phase 2 Paclitaxel protein bound;Cisplatin;Gemcitabine;Paricalcitol
43 Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
44 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON) Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
45 Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer Recruiting NCT03498326 Phase 2 Gemcitabine;Gemcitabine
46 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
47 Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study Recruiting NCT02677038 Phase 2 Olaparib
48 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
49 A Phase II Study of Pancreatic Enzyme Replacement (Zenpep) on Completion Rates of Adjuvant Chemotherapy Among Subjects With Resected Pancreatic Ductal Adenocarcinoma Recruiting NCT03469258 Phase 2 Pancrelipase
50 PRIMUS002: An Umbrella Phase II Study Examining Two Neo-adjuvant Regimens (FOLFOX-A and AG) in Resectable and Borderline Resectable Pancreatic Ductal AdenoCarcinoma (PDAC), Focusing on Biomarker and Liquid Biopsy Development Recruiting NCT04176952 Phase 2 FOLFOX-A;AG
51 A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS Recruiting NCT03637491 Phase 2 Avelumab;Binimetinib;Talazoparib
52 Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03634332 Phase 2 PEGPH20
53 A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant Immunotherapy Based Combinations in Patients With Resectable PANCreatic Ductal Adenocarcinoma Recruiting NCT03979066 Phase 2 Atezolizumab;PEGPH20
54 Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
55 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Recruiting NCT03410030 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
56 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib;Cediranib Maleate;Olaparib
57 A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD) Recruiting NCT03415854 Phase 2 Paricalcitol (Zemplar)
58 A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer Recruiting NCT03487016 Phase 2 Gemcitabine;Nab-paclitaxel;5-FU;Irinotecan Liposomal Injection;Oxaliplatin
59 An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2 Cisplatin;Gemcitabine;Nab-paclitaxel
60 A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
61 Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy Recruiting NCT03264404 Phase 2 Pembrolizumab;Azacitidine
62 A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1) Recruiting NCT02758587 Phase 1, Phase 2 Defactinib;Pembrolizumab
63 Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
64 Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer Recruiting NCT03693677 Phase 2 Irinotecan Liposomal Injection;5-FU/LV;Nab-Paclitaxel;Gemcitabine
65 Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
66 A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT03444948 Phase 2 Standard therapy
67 A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection Active, not recruiting NCT02178709 Phase 2 FOLFIRINOX
68 A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
69 A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors Active, not recruiting NCT02880371 Phase 1, Phase 2 ARRY-382;Pembrolizumab
70 A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Active, not recruiting NCT03085914 Phase 1, Phase 2 Epacadostat;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin;Cisplatin
71 Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Active, not recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
72 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT03611556 Phase 1, Phase 2
73 A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
74 A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
75 Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas Active, not recruiting NCT02839343 Phase 2 mFOLFIRINOX;FOLFOX
76 UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer Not yet recruiting NCT04134468 Phase 2 Pegvorhyaluronidase alfa;Abraxane;Gemcitabine
77 A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs). Not yet recruiting NCT03767582 Phase 1, Phase 2 Nivolumab;CCR2/CCR5 dual antagonist;GVAX
78 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet
79 A Phase II Study of S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer (SIROX Study) - Followed by Curative Surgery and Adjuvant Chemotherapy Not yet recruiting NCT03316326 Phase 2 Tegafur-gimeracil-oteracil potassium;Oxaliplatin;Irinotecan
80 Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Metastatic Pancreatic Adenocarcinoma (ALIX) Not yet recruiting NCT03974854 Phase 2 XELOXIRI-3;Gemcitabine
81 An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX) Not yet recruiting NCT03450018 Phase 1, Phase 2 SLC-0111;Gemcitabine Injection
82 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Not yet recruiting NCT04146441 Phase 2 Chemotherapy
83 A Single Arm Phase 2 Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. Not yet recruiting NCT04045730 Phase 2 Gemcitabine
84 Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel Not yet recruiting NCT03666832 Phase 1, Phase 2 TEW-7197
85 A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy Not yet recruiting NCT04111172 Phase 2
86 An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain Suspended NCT00637364 Phase 1, Phase 2
87 A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone, in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR PDA) Following Neoadjuvant Therapy and Successful Surgical Resection Terminated NCT03038477 Phase 2 Durvalumab
88 PHASE 1/2 STUDY OF PF-03084014 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Terminated NCT02109445 Phase 2 PF-03084014;Gemcitabine;Nab-paclitaxel;PF-03084014;Gemcitabine;Nab-paclitaxel;Gemcitabine;Nab-paclitaxel
89 Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period Terminated NCT01096732 Phase 2 GDC-0449
90 PHASE 1B/2 STUDY OF PF-04136309 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Terminated NCT02732938 Phase 2 PF-04136309;Nab-paclitaxel;Gemcitabine
91 Phase 2 Evaluation of a Community-Based Multi-modality Management Algorithm for Clinically Non-metastatic Ductal Adenocarcinoma of the Exocrine Pancreas or Ampulla Terminated NCT02626520 Phase 2 Gemcitabine and nanoparticle albumin bound paclitaxel;5-fluorouracil and irinotecan
92 Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. Terminated NCT01431794 Phase 1, Phase 2 LDE225-600mg;Gemcitabine;nab-paclitaxel;LDE225-400mg;LDE225-800mg
93 A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors Terminated NCT03681951 Phase 2 GSK3145095;Pembrolizumab
94 Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) - A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer Terminated NCT02124369 Phase 2 Abraxane;Gemcitabine
95 Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging Terminated NCT02736578 Phase 2 Cetuximab-IRDye800;Cetuximab
96 A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status Withdrawn NCT03374852 Phase 2 CPI-613;mFOLFIRNOX
97 Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas Withdrawn NCT01600807 Phase 1, Phase 2 Gemcitabine, Erlotinib, OSI-906;Gemcitabine, Erlotinib
98 A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma Withdrawn NCT03065985 Phase 2 Standard chemotherapy
99 Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer Withdrawn NCT04130399 Phase 2 FOLFIRINOX
100 Hyperthermic Intraperitoneal Chemotherapy as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: A Prospective, Phase II, Proof-of-concept Study Withdrawn NCT02850874 Phase 2 Gemcitabine
101 A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients Withdrawn NCT02575508 Phase 1, Phase 2 Fluorouracil;Irinotecan Hydrochloride;Oxaliplatin;pan FGFR Kinase Inhibitor BGJ398
102 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Withdrawn NCT03697239 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
103 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Withdrawn NCT03908333 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
104 A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients Unknown status NCT02021422 Phase 1 anakinra;Oxaliplatin;Irinotecan;fluorouracil
105 Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Unknown status NCT01934634 Phase 1 LCL161;Gemcitabine;nab-Paclitaxel
106 A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02657330 Phase 1 SBP-101
107 Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas Completed NCT01188785 Phase 1 siG12D LODER
108 Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers Completed NCT02159716 Phase 1
109 Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer Completed NCT01897415 Phase 1
110 Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma Completed NCT00547612 Phase 1
111 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
112 AN OPEN-LABEL PHASE IB STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS ABRAXANE (REGISTERED) (NAB-PACLITAXEL) IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Completed NCT02501902 Phase 1 Palbociclib;Nab-Paclitaxel
113 A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia Completed NCT00985777 Phase 1 Vitamin E δ-Tocotrienol
114 Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03412799 Phase 1 SBP-101;nab-paclitaxel;Gemcitabine Injection
115 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of Combined Therapy With ATR Inhibitor AZD6738 and Gemcitabine, Using a Model Based Design. Recruiting NCT03669601 Phase 1 AZD6738;Gemcitabine
116 A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors Recruiting NCT03076372 Phase 1 MM-310
117 A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy Recruiting NCT03883919 Phase 1 5-FU;Leucovorin;Liposomal Irinotecan;Paricalcitol
118 SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer Recruiting NCT04106856 Phase 1 Losartan;Losartan Potassium
119 Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer Recruiting NCT03592888 Phase 1 mDC3/8-KRAS Vaccine
120 Phase I Trial of the Combination of PS101-Mediated Acoustic Cluster Therapy (ACT) With Chemotherapy for Treatment of Liver Metastasis In Patients With Solid Tumours With an Expansion Cohort in Metastatic Colorectal And Pancreatic Cancer Recruiting NCT04021277 Phase 1
121 Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy Recruiting NCT03851237 Phase 1 64Cu-DOTA-ECLIi
122 CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma. Recruiting NCT03871959 Phase 1 Pembrolizumab;DEBIO1143
123 Study of Talimogene Laherparepvec Administered Endoscopically for the Treatment of Locally Advanced or Metastatic Pancreas Cancer Refractory to at Least One Chemotherapy Regimen Recruiting NCT03086642 Phase 1 Talimogene laherparepvec
124 A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Recruiting NCT04034238 Phase 1 LMB-100;Tofacitinib
125 A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer Active, not recruiting NCT03517176 Phase 1 CEND-1;Nab-paclitaxel;Gemcitabine
126 Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Active, not recruiting NCT02600949 Phase 1 Imiquimod
127 Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial Active, not recruiting NCT02975141 Phase 1 Afatinib 30Mg Tab;Afatinib 40Mg Tab;Gemzar;Abraxane
128 A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors Active, not recruiting NCT03415126 Phase 1 ASN007: ascending doses;ASN007 RD
129 A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine Active, not recruiting NCT02959164 Phase 1 Decitabine;Gemcitabine
130 A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Active, not recruiting NCT02777710 Phase 1 Pexidartinib;Durvalumab
131 Phase I Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Not yet recruiting NCT04046887 Phase 1 Lonsurf;Gemcitabine;Nab-Paclitaxel
132 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer Not yet recruiting NCT04117087 Phase 1 KRAS peptide vaccine;Nivolumab;Ipilimumab
133 Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation Not yet recruiting NCT03608631 Phase 1 Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
134 A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02468557 Phase 1 Idelalisib;Nab-paclitaxel;mFOLFOX6
135 A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02244489 Phase 1 Momelotinib (MMB);Capecitabine;Oxaliplatin
136 Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study Terminated NCT02782182 Phase 1 FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
137 A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy Unknown status NCT02929797 Early Phase 1 Gemcitabine
138 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
139 Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
140 Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] Unknown status NCT01879878
141 Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells Unknown status NCT01921699
142 Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma Unknown status NCT01713218 Early Phase 1 gemcitabine;Vismodegib
143 Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma Unknown status NCT01715142 Early Phase 1 Gemcitabine;Abraxane
144 Compare More Distal Enteral Bypass With Standard Enteral Bypass in the Remission of Glucose Metabolism for Patients With Diabetes or Impaired Fasting Glucose After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial Unknown status NCT01755273
145 Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study Completed NCT01155882
146 Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC Completed NCT03032913
147 Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer Completed NCT00826982
148 CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study Completed NCT00588367
149 Impatto Della Revisione Radiologica Con Valutazione Multidisciplinare Nella Gestione Terapeutica Dei Pazienti Affetti da Adenocarcinoma Pancreatico (PAC) Completed NCT03973736
150 Long-term Benefit of Elderly Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy Completed NCT03659903
151 Evaluation of NGS in Combination With an Oncology Treatment Decision Support Software for Evidence-based Priorization of Individualised Treatment in Patients With Pancreatic Cancer Completed NCT02767700
152 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
153 Yield Rate for Procurement the Histologic Core With Endoscopic Ultrasound-guided Fine Needle Biopsy With 20-gauge Ultrasound Biopsy Needles for Solid Pancreatic Masses: Pilot Study Completed NCT03017599
154 Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy Completed NCT03042442
155 Pancreatic Juice Diagnosis From Duodenum Completed NCT01699698
156 Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) Completed NCT00714701
157 Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study Completed NCT01821612 Early Phase 1 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
158 A Prospective Randomized Trial of Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction Completed NCT01038713
159 Utility of EUS-guided Microbiopsies Combined With Auxiliary Molecular Techniques in the Workup of Pancreatic Cystic Lesions Completed NCT03578445
160 PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma Recruiting NCT04099134
161 Advancing The Local Staging Of Pancreatic Ductal Adenocarcinoma Through High-Resolution Ultrasound: A Pilot Study Recruiting NCT03820661
162 A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma Recruiting NCT01983410
163 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308
164 A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma Recruiting NCT03890198 Early Phase 1
165 Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (PDAC Plasma Biomarker Study) Recruiting NCT02050997
166 Ablation of Unresectable Locally Advanced Pancreatic Cancer With Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability Recruiting NCT03614910
167 A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer Recruiting NCT03568630
168 Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial Recruiting NCT03257150 18F-Fluoroazomycin arabinoside
169 A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations Recruiting NCT03693378
170 Periampullary Lesions Via ERCP in Assuit University Hospital Recruiting NCT03185390
171 Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma Recruiting NCT03334708
172 Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial Recruiting NCT03400072
173 Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial Recruiting NCT03772756
174 A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer Recruiting NCT04115527
175 Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Recruiting NCT04133155 nab paclitaxel plus gemcitabine
176 Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers Recruiting NCT02361320
177 A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer Recruiting NCT04024358
178 Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB) Recruiting NCT03990675
179 Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy(TJDBPS01) a Multicenter Randomized Controlled Trial Recruiting NCT03138213
180 A Pilot Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease Recruiting NCT03770117
181 The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled WAter or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma Recruiting NCT02757859
182 Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis Recruiting NCT02869802
183 Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer Recruiting NCT03492164 Early Phase 1 [18F]FluorThanatrace ([18F]FTT)
184 Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer Recruiting NCT03117556
185 Multicenter Prospective Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Distal Pancreatectomy for Ductal Adenocarcinoma of the Pancreatic Body and Tail Recruiting NCT03957135
186 A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic Neuroendocrine Tumours (PanNETs) to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers Recruiting NCT03840460
187 Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds Biomarkers in Bile and Serum in the Diagnosis of Malignant Biliary Strictures Recruiting NCT02531607
188 Phase 1 Window of Opportunity Study of Parasympathetic Stimulation With Bethanechol in Localized Pancreatic Adenocarcinoma Prior to Surgery Recruiting NCT03572283 Early Phase 1 Bethanechol
189 Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image-guided Radiotherapy for Pancreatic Adenocarcinoma Recruiting NCT03307564
190 Discovery of New Biomarkers in Pancreatic Cancer Using Novel Nondestructive OMICS Methodology Recruiting NCT03791073
191 Pancreas Disease and High Risk Registry Recruiting NCT02775461
192 Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer Recruiting NCT04112836
193 Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis Recruiting NCT03524677
194 Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis Recruiting NCT03098082
195 Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer in Consecutive Cases Unselected for Family History Active, not recruiting NCT02790944
196 A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer Active, not recruiting NCT02787187
197 Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study Active, not recruiting NCT01104129
198 Prevalence of Germline Pathogenic Mutations in Patients With Pancreatic Adenocarcinoma Active, not recruiting NCT03982446
199 Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery Enrolling by invitation NCT03687853
200 Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer Enrolling by invitation NCT03012282
201 Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program Not yet recruiting NCT03865875
202 Short and Long Term Outcomes of Whipples Resection in the Over 80s Not yet recruiting NCT03813368
203 PD-L1 and MMR Status Provided by Endoscopic Ultrasound-Guided Fine-Needle Biopsies as a Predictor of PrognosiS in Patients With Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT03820921
204 The Role of Endoscopic Ultrasound Radiofrequency Ablation (EUS RFA) in the Management of Not Resectable Pancreatic Cancer. Not yet recruiting NCT04164992
205 EUS-guided Laser Complete Ablation of Advanced Pancreatic Ductal Adenocarcinoma: a Feasibility Study Not yet recruiting NCT03784417
206 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Not yet recruiting NCT03432624
207 Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms Not yet recruiting NCT03435770
208 A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma Terminated NCT01962909 Early Phase 1 PTP-01
209 A Pilot Trial of PEGPH20 (Pegylated Hyaluronidase) in Combination With Avelumab (Anti-PD-L1 MSB0010718C) in Chemotherapy Resistant Pancreatic Cancer Terminated NCT03481920 Early Phase 1 PEGylated Recombinant Human Hyaluronidase (PEGPH20);Avelumab
210 BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis Terminated NCT01103128
211 Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia Terminated NCT02580422
212 Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST) Terminated NCT02670746
213 Randomized Controlled Trial Comparing Radiofrequency Ablation and Stenting vs. Stenting Alone for Biliary Obstruction Due to Unresectable Cholangiocarcinoma and Pancreatic Cancer Terminated NCT02166190
214 A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer Withdrawn NCT01911416 LDE225
215 Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance Withdrawn NCT02414100

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

40
Pancreas, T Cells, Lymph Node, Liver, Lung, Neutrophil, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(showing 7550, show less)
# Title Authors PMID Year
1
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. 61 46
21088996 2011
2
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. 61 46
21068491 2010
3
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. 61 46
20093556 2010
4
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. 61 46
19723895 2009
5
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. 61 46
18719196 2008
6
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. 61 46
17237814 2007
7
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. 46
19551852 2010
8
Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma. 61
31583713 2020
9
Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. 61
31857154 2020
10
Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. 61
31792715 2020
11
TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. 61
31177911 2020
12
FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma. 61
31692063 2020
13
Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. 61
31562239 2020
14
Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. 61
31801873 2020
15
SOX2OT, a novel tumor-related long non-coding RNA. 61
31865145 2020
16
Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. 61
31871136 2020
17
Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry. 61
32029124 2020
18
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. 61
31340061 2020
19
Impact of structured report on the quality of preoperative CT staging of pancreatic ductal adenocarcinoma: assessment of intra- and inter-reader variability. 61
31686180 2020
20
Shear Wave Elastography Can Differentiate between Radiation-Responsive and Non-responsive Pancreatic Tumors: An ex Vivo Study with Murine Models. 61
31727378 2020
21
Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. 61
31602815 2020
22
Characterization of the metastatic potential of the floating cell component of MIA PaCa-2, a human pancreatic cancer cell line. 61
31806369 2020
23
Microglia in the hypothalamus respond to tumor-derived factors and are protective against cachexia during pancreatic cancer. 61
32039522 2020
24
miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. 61
31662451 2020
25
2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. 61
31811906 2020
26
Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway. 61
32027944 2020
27
Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy. 61
31463596 2020
28
Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus. 61
31904730 2020
29
Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. 61
31894273 2020
30
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. 61
31699795 2020
31
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment. 61
32014869 2020
32
Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells. 61
32014914 2020
33
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. 61
31787751 2020
34
A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. 61
32024063 2020
35
EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. 61
32036221 2020
36
Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct. 61
31678302 2020
37
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. 61
31789476 2020
38
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. 61
31605325 2020
39
Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. 61
32029502 2020
40
Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications. 61
32023088 2020
41
Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? 61
32018143 2020
42
MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. 61
32002032 2020
43
Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. 61
31466841 2020
44
Cancer-cell-derived matrisome proteins promote metastasis in pancreatic ductal adenocarcinoma. 61
32029550 2020
45
BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. 61
32029896 2020
46
Pancreatic ductal adenocarcinoma: tumor regression grading following neoadjuvant FOLFIRINOX and Radiation. 61
32031712 2020
47
Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. 61
31201285 2020
48
Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells. 61
31822343 2020
49
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma. 61
31974610 2020
50
Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma. 61
31783084 2020
51
Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. 61
31694889 2020
52
Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma. 61
32037002 2020
53
Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras. 61
31760766 2020
54
CNN-based survival model for pancreatic ductal adenocarcinoma in medical imaging. 61
32013871 2020
55
ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36. 61
31659646 2020
56
Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms. 61
31808619 2020
57
A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality. 61
30188400 2020
58
PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. 61
31520395 2020
59
Differential Contributions of Actin and Myosin to the Physical Phenotypes and Invasion of Pancreatic Cancer Cells. 61
32030106 2020
60
Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. 61
32032721 2020
61
Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer. 61
31595972 2020
62
Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. 61
32031201 2020
63
Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. 61
32009482 2020
64
B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. 61
32024640 2020
65
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. 61
31705130 2020
66
Pitfalls in the MDCT of pancreatic cancer: strategies for minimizing errors. 61
31897686 2020
67
Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B. 61
31816384 2020
68
Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. 61
32039571 2020
69
Volume changes of the pancreatic head remnant after distal pancreatectomy. 61
31630778 2020
70
MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. 61
32039734 2020
71
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. 61
31512195 2020
72
High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. 61
31966084 2020
73
Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. 61
31799875 2020
74
Statins Limit Coenzyme Q Synthesis and Metabolically Synergize with MEK Inhibition in Pancreatic Tumors. 61
31941676 2020
75
MicroRNA-628-5p inhibits invasion and migration of human pancreatic ductal adenocarcinoma via suppression of the AKT/NF-kappa B pathway. 61
31957029 2020
76
Development and characterization of a 68Ga-labeled A20FMDV2 peptide probe for the PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma. 61
31740201 2020
77
Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study. 61
31882498 2020
78
Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma. 61
31991068 2020
79
Dual-layer spectral CT improves image quality of multiphasic pancreas CT in patients with pancreatic ductal adenocarcinoma. 61
31312889 2020
80
Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. 61
31856087 2020
81
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. 61
31949002 2020
82
Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. 61
31685560 2020
83
ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. 61
31903112 2020
84
m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. 61
31906946 2020
85
Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. 61
31913868 2020
86
Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. 61
31935830 2020
87
Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. 61
31754050 2020
88
Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. 61
31706821 2020
89
A four-chemokine signature is associated with a T cell-inflamed phenotype in primary and metastatic pancreatic cancer. 61
31964786 2020
90
Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. 61
31719057 2020
91
Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells. 61
31968611 2020
92
FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. 61
31935687 2020
93
Recent trends in the incidence and survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results analysis. 61
31958122 2020
94
Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells. 61
31694943 2020
95
Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2). 61
31819190 2020
96
Plasma Membrane Ca2+ ATPase Isoform 4 (PMCA4) Has an Important Role in Numerous Hallmarks of Pancreatic Cancer. 61
31963119 2020
97
Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor. 61
31963309 2020
98
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. 61
31997233 2020
99
Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. 61
31943574 2020
100
Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study. 61
31672679 2020
101
GNG12 regulates PD-L1 expression by activating NF-κB signaling in pancreatic ductal adenocarcinoma. 61
31898405 2020
102
The Microarchitecture of Pancreatic Cancer as Measured by Diffusion-Weighted Magnetic Resonance Imaging Is Altered by T Cells with a Tumor Promoting Th17 Phenotype. 61
31948053 2020
103
The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. 61
31954769 2020
104
External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. 61
31711795 2020
105
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). 61
31912800 2020
106
Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma. 61
31771041 2020
107
Personalizing KRAS-Mutant Allele-Specific Therapies. 61
31919121 2020
108
Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. 61
32024004 2020
109
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. 61
31765987 2020
110
Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase. 61
31953587 2020
111
The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma. 61
31988076 2020
112
Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. 61
31985457 2020
113
3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. 61
31947550 2020
114
Effects of Immunonutrition on Comprehensive Complication Index in Patients Undergoing Pancreatoduodenectomy. 61
31991566 2020
115
Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review. 61
30970350 2020
116
KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells. 61
31610265 2020
117
Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. 61
31473224 2020
118
Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance. 61
31780287 2020
119
Dynamin 2 interacts with alpha-actinin 4 to drive tumor cell invasion. 61
31967944 2020
120
A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. 61
31997571 2020
121
The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. 61
31900809 2020
122
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression. 61
31897200 2020
123
Fucosyltransferase 8 plays a crucial role in the invasion and metastasis of pancreatic ductal adenocarcinoma. 61
31950256 2020
124
Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. 61
31920150 2020
125
Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC). 61
31929143 2020
126
Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. 61
31435922 2020
127
Microbiota in pancreatic health and disease: the next frontier in microbiome research. 61
31811279 2020
128
Consumption of nuts and seeds and pancreatic ductal adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition. 61
31107546 2020
129
Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. 61
31892968 2020
130
PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma. 61
31897122 2020
131
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. 61
31841792 2020
132
Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. 61
31477830 2020
133
Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study. 61
32000852 2020
134
PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. 61
32005189 2020
135
Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma. 61
31941049 2020
136
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? 61
31856098 2020
137
Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. 61
31894482 2020
138
Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. 61
31959787 2020
139
MiR-497 inhibits cell proliferation and invasion ability by targeting HMGA2 in pancreatic ductal adenocarcinoma. 61
31957824 2020
140
Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. 61
31941533 2020
141
Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. 61
31872760 2020
142
Microscopic Size Measurements Predict Outcomes in Post-Neoadjuvant Resections of Pancreatic Ductal Adenocarcinoma (PDAC). 61
31965618 2020
143
The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in Patients with Pancreatic Ductal Adenocarcinoma. 61
32021451 2020
144
Pancreatoduodenectomy with venous resection for ductal adenocarcinoma rarely achieves complete (R0) resection. 61
31186199 2020
145
Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. 61
31262486 2020
146
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models. 61
32009658 2020
147
Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. 61
32011525 2020
148
The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. 61
32011535 2020
149
CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells. 61
32007357 2020
150
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. 61
31993761 2020
151
Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. 61
31996388 2020
152
[Organoids from pancreatic ductal adenocarcinoma]. 61
32014099 2020
153
Proteome alterations in pancreatic ductal adenocarcinoma. 61
31734355 2020
154
Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. 61
31895430 2020
155
Myc instructs and maintains pancreatic adenocarcinoma phenotype. 61
31941709 2020
156
Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. 61
31759906 2020
157
Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. 61
31960765 2020
158
KANSL2 and MBNL3 are regulators of pancreatic ductal adenocarcinoma invasion. 61
32001790 2020
159
Recurrence After Resection of Pancreatic Ductal Adenocarcinoma-Reply. 61
31895438 2020
160
Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. 61
31481506 2020
161
Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. 61
31585935 2020
162
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. 61
31613799 2020
163
Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer. 61
32004866 2020
164
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. 61
32007666 2020
165
BACH1 promotes pancreatic cancer metastasis by repressing epithelial genes and enhancing epithelial-mesenchymal transition. 61
31919242 2020
166
Tumor Cell-Derived IL-1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. 61
31915130 2020
167
Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. 61
31597713 2020
168
Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer. 61
31938057 2020
169
Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. 61
31908093 2020
170
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. 61
31076405 2020
171
lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCFβ-TRCP-Mediated Degradation of NRF2 in Pancreatic Cancer. 61
32036249 2020
172
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. 61
31830001 2020
173
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. 61
31649109 2020
174
Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. 61
31746520 2020
175
TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. 61
31705846 2020
176
Predicted Prognosis of Pancreatic Cancer Patients by Machine Learning. 61
31992588 2020
177
The enhancement of glycolysis regulates pancreatic cancer metastasis. 61
31432232 2020
178
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. 61
32001555 2020
179
Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. 61
31672677 2020
180
ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. 61
31582374 2020
181
Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. 61
31856088 2020
182
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. 61
31892563 2020
183
Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. 61
31944405 2020
184
ATM Serine/Threonine Kinase and its Role in Pancreatic Risk. 61
31963441 2020
185
MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. 61
32012923 2020
186
DLEU1: A functional long noncoding RNA in tumorigenesis. 61
31969095 2020
187
Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. 61
31901178 2020
188
Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. 61
31715081 2020
189
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. 61
28972449 2020
190
TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer. 61
31986125 2020
191
Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. 61
31959629 2020
192
Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. 61
31960942 2020
193
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. 61
31787526 2020
194
Mitochondrial DNA copy number variation and pancreatic cancer risk in the prospective EPIC cohort. 61
31932413 2020
195
Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). 61
31676330 2020
196
PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation. 61
31989778 2020
197
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. 61
31983610 2020
198
Triple Drugs Co-Delivered by a Small Gemcitabine-Based Carrier for Pancreatic Cancer Immunochemotherapy. 61
32004652 2020
199
Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. 61
32005355 2020
200
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. 61